Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser

Autor: Myrte B. Breukink, Petrus J.H. Peters, Camiel J. F. Boon, Sascha Fauser, Roula Tsonaka, Thomas J. van Rijssen, Robert E MacLaren, Susan M. Downes, Carel B. Hoyng, Paula Scholz, Elon H. C. van Dijk, Jan E.E. Keunen, Greet Dijkman
Přispěvatelé: Ophthalmology
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
micropulse laser
Time Factors
Visual acuity
medicine.medical_treatment
Visual Acuity
Photodynamic therapy
long-term follow-up
Chronic central serous chorioretinopathy
Sensory disorders Donders Center for Medical Neuroscience [Radboudumc 12]
chemistry.chemical_compound
0302 clinical medicine
Prospective Studies
Fluorescein Angiography
Photosensitizing Agents
General Medicine
Diabetic retinopathy
Middle Aged
Treatment Outcome
photodynamic therapy
Original Article
Female
Laser Therapy
medicine.symptom
Tomography
Optical Coherence
medicine.medical_specialty
Fundus Oculi
Long term follow up
Retina
03 medical and health sciences
Ophthalmology
medicine
Humans
In patient
central serous chorioretinopathy
Choroid
business.industry
Verteporfin
Retinal
Original Articles
medicine.disease
eye diseases
Photochemotherapy
chemistry
long‐term follow‐up
030221 ophthalmology & optometry
business
Microperimetry
030217 neurology & neurosurgery
Follow-Up Studies
Zdroj: Acta Ophthalmologica (2008), 99, 805-811
Acta ophthalmologica, 99(7), 805-811. Copenhagen Scriptor
Acta Ophthalmologica, 99(7), 805-811. WILEY
Acta Ophthalmologica
Acta Ophthalmologica (2008), 99, 7, pp. 805-811
ISSN: 1755-375X
Popis: Contains fulltext : 244034.pdf (Publisher’s version ) (Open Access) PURPOSE: To describe the treatment outcomes and recurrence risk of chronic central serous chorioretinopathy (cCSC) in patients who had complete resolution of subretinal fluid (SRF) after either primary half-dose photodynamic therapy (PDT) or high-density subthreshold micropulse laser (HSML) in the PLACE trial. METHODS: This multicentre prospective follow-up study evaluated cCSC patients at 1 year after completion of the PLACE trial. Outcomes included: complete resolution of SRF on OCT, best-corrected visual acuity (BCVA) in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, retinal sensitivity on microperimetry and a visual function questionnaire (NEI-VFQ25). RESULTS: Twenty-nine out of 37 patients who received half-dose PDT and 15 out of 17 patients who received HSML could be evaluated at final visit. At final visit, 93% of the patients treated with half-dose PDT had complete resolution of SRF, compared with 53% of HSML-treated patients (p = 0.006). At final visit, the mean estimate increase in the PDT group compared with the HSML group was + 2.1 ETDRS letters, +0.15 dB for the retinal sensitivity and + 5.1 NEI-VFQ25 points (p = 0.103, p = 0.784 and p = 0.071, respectively). The mean estimated central retinal thickness in the half-dose PDT group was -7.0 µm compared with the HSML group (p = 0.566). The mean estimated subfoveal choroidal thickness in the half-dose PDT group was -16.6 µm compared with the HSML group (p = 0.359). CONCLUSION: At 20 months after treatment, cCSC patients successfully treated with half-dose PDT are less likely to have recurrences of SRF compared with those successfully treated with HSML. However, functional outcomes did not differ.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje